Abstracts tagged "SLE"

Abstract Number: 308 • 2019 ACR/ARP Annual Meeting
Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays
Konrad Dziamski¹ and Andras Perl ¹, ¹SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Indirect immunofluorescence (IF) is the recommended initial test for detection of antinuclear antibodies (ANA) by the American College of Rheumatology (Ann Rheum. Dis 69:1420-2),…
Abstract Number: 704 • 2019 ACR/ARP Annual Meeting
Improving Patient-Centered Care by Utilizing Lupus Wellness Program
Jacinta Renaldi¹, Fotios Koumpouras ¹, Lenore Buckley ¹ and Mei Xue Dong ¹, ¹Yale University, New Haven
Background/Purpose: Although the mortality rate of lupus has decreased with improvement of treatment options, it remains high compared to non-SLE mortality. The factors that contribute…
Abstract Number: 1148 • 2019 ACR/ARP Annual Meeting
Examining Five Year Lupus Retention in Care in an Academic Cohort
Christie Bartels¹ and Maria Schletzbaum ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: SLE often causes silent damage, making routine clinic and lab monitoring critical for detecting new manifestations or flares. The 2012 ACR nephritis guidelines recommended…
Abstract Number: 1620 • 2019 ACR/ARP Annual Meeting
T-cell Exhaustion in Prolonged Remission SLE Patients
Francisco Treviño-Tello¹, Guadalupe Lima ¹, Juan Jakez-Ocampo ², Luis Llorente ¹, Yemil Atisha-Fregoso ¹ and Hilda Fragoso-Loyo ³, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico
Background/Purpose: Cellular exhaustion is a cellular dysfunction characterized by the progressive loss of the effector function, and an increased expression of multiple inhibitory receptors. Exhaustion…
Abstract Number: 2520 • 2019 ACR/ARP Annual Meeting
Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial
Richard Furie¹, Darrin Bomba ², Maria Dall'Era ³, Amber Khan ⁴, Miguel Soneira ⁴, Janet Anderl ², Jinhai Wang ², Christopher Kirk ² and Niti Goel ⁵, ¹Northwell Health, Great Neck, NY, ²Kezar Life Sciences, SOUTH SAN FRANCISCO, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Accurate Clinical Research, Houston, TX, ⁵Kezar Life Sciences, Duke University School of Medicine, South San Francisco, CA
Background/Purpose: Nonspecific proteasome inhibitors, eg, bortezomib (BTZ), target both the constitutive and immuno- proteasome and are approved for the treatment of multiple myeloma. While BTZ…
Abstract Number: 640 • 2019 ACR/ARP Annual Meeting
Elevated Serum Interleukin-23 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity, Clinical and Immunological Markers
Milena Vukelic¹, Anita Laloo ² and Vasileios Kyttaris ³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Rheumatology Practice, Fort Lauderdale, FL, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a autoimmune disease characterized by deregulated cytokine production. IL-23 bridges innate and adaptive immunity by inducing the differentiation of…
Abstract Number: 705 • 2019 ACR/ARP Annual Meeting
A Tale of Three Cohorts: SLE Criteria in Developed vs Developing Countries
Ashira Blazer¹, Allison Guttmann ¹, Ida Dzifa Dey ², Olusola Ayanlowo ³, Uyi Ima-Edomwonyi ³, Hakeem Olasebikan ³, Margaret Reynolds ³, Festus Ankrah ², Jill Buyon ⁴ and Olufemi Adelowo ⁵, ¹NYU School of Medicine, New York, NY, ²Korle bu Teaching Hospital, Accra, Ghana, ³Lagos University Teaching Hospital, Lagos, Nigeria, ⁴NYU School of Medicine, New York, ⁵Lagos State University Teaching Hospital, Lagos, Nigeria
Background/Purpose: SLE diagnostic criteria are important for reliable epidemiologic data. The prevalence of SLE in West Africa is falsely low due to barriers including limited…
Abstract Number: 1191 • 2019 ACR/ARP Annual Meeting
Application of the Systemic Lupus Erythematosus (SLE) Quality Indicators in Patients Attending a Young Adult Transition Program
Aos Aboabat¹, Earl D. Silverman ² and Amanda Steiman ¹, ¹University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, University of Toronto, Translational Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada
Background/Purpose: Systemic lupus erythematosus is a multisystemic rheumatic disease affecting 1 in 1000 individuals with a 10:1 female predominance. Childhood-onset SLE (CSLE) constitutes approximately 15%…
Abstract Number: 1732 • 2019 ACR/ARP Annual Meeting
Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients
Catherine Strahle¹, Angela Merritt ², Xiaoling Niu ³, Arjun Mathur ⁴, Allen Watts ² and Hermine Brunner ⁵, ¹Univeristy of Cincinnati Medical Center, Cincinnati, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Fudan University, Shanghai, Shanghai, China (People's Republic), ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: The traditional 1997 ACR SLE classification criteria classify a patient as having SLE if 4 of the 11 criteria have been met over time.…
Abstract Number: 2537 • 2019 ACR/ARP Annual Meeting
Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Jianlin Huang¹, Yongfu Wang ², Hua Wei ³, Jing Yang ⁴, Tong Xie ⁵, Hongzhi Wang ⁶, Xiaohan Wang ⁷, Yu Zhang ⁴, Cheng Zhao ⁸, Jinmei Zou ⁴, Fang He ⁹, Jinli Ru ¹⁰, Henglian Wu ¹¹, Guosheng Wang ¹², Lingyun Sun ¹³, Shengqian Xu ¹⁴, Yanjie Hao ¹⁵, Xiangpei Li ¹⁶, Zhijun Li ¹⁷, Bing Wu ¹⁸, Yuhua Jia ¹⁹, Yuan Liu ²⁰, Hui Xiao ²⁰, Fei Xiao ²¹ and Chunde Bao ²², ¹The sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (People's Republic), ²The First Affiliated Hospital of BaoTou Medical College, Baotou, Nei Mongol, China (People's Republic), ³Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China (People's Republic), ⁴Central Hospital of MianYang, Mianyang, Sichuan, China (People's Republic), ⁵Affiliated hospital of Guangdong medical University, Zhanjiang, Guangdong, China (People's Republic), ⁶JiaXing First Hospital, Jiaxing, Zhejiang, China (People's Republic), ⁷Anyang district hospital, Fuyang, Hainan, China (People's Republic), ⁸The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ⁹Suining Central Hospital, suining, China (People's Republic), ¹⁰The Second Hospital of Shanxi Medical University, Shanxi, Shanxi, China (People's Republic), ¹¹Dongguan donghua hospital, Dongguan, Guangdong, China (People's Republic), ¹²Anhui Provincial Hospital, Hefei, Anhui, China (People's Republic), ¹³The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic), ¹⁴First Affiliated Hospital of Medical University Of Anhui, Hefei, Anhui, China (People's Republic), ¹⁵Peking University First Hospital; Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic), ¹⁶Anhui Provincial Hospital, Heifei, Anhui, China (People's Republic), ¹⁷The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China (People's Republic), ¹⁸Shanghai Gothic Internet Technology Co., Ltd, Shanghai, China (People's Republic), ¹⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ²⁰Shanghai Gothic Internet Technology Co., Ltd, Shanghai, Shanghai, China (People's Republic), ²¹Shanghai Gothic Internet Technology Co., Ltd., shanghai, China (People's Republic), ²²Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Treating to target is routine in rheumatoid arthritis, but no comparable standard has been defined for SLE. In 2015, the definition of Lupus Low Disease Activity State (LLDAS) was…
Abstract Number: 647 • 2019 ACR/ARP Annual Meeting
Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort?
May Choi¹, Megan Barber ², Marvin Fritzler ¹, John G Hanly ³, Murray Urowitz ⁴, Yvan St-Pierre ⁵, Juanita Romero-Diaz ⁶, Caroline Gordon ⁷, Sang-Cheol Bae ⁸, Sasha Bernatsky ⁹, Daniel J Wallace ¹⁰, David A Isenberg ¹¹, Anisur Rahman ¹², Ellen M Ginzler ¹³, Michelle Petri ¹⁴, Ian Bruce ¹⁵, Paul Fortin ¹⁶, Dafna Gladman ¹⁷, Jorge Sanchez-Guerrero ¹⁸, Rosalind Ramsey-Goldman ¹⁹, Munther A Khamashta ²⁰, Cynthia Aranow ²¹, Meggan Mackay ²², Graciela Alarcón ²³, Susan Manzi ²⁴, Ola Nived ²⁵, Andreas Jönsen ²⁵, Asad Zoma ²⁶, Ronald van Vollenhoven ²⁷, Manuel Ramos-Casals ²⁸, Guillermo Ruiz-Irastorza ²⁹, S Sam Lim ³⁰, Kenneth C Kalunian ³¹, Murat Inanc ³², Diane Kamen ³³, Christine Peschken ³⁴, Soren Jacobsen ³⁵, Anca Askanase ³⁶, Vernon Farewell ³⁷ and Ann E Clarke ³⁸, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²University of Calgary, Calgary, Canada, ³Dalhousie University, Halifax, NS, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada, ⁵McGill University Health Centre, Montreal, QC, Canada, ⁶Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰Cedars-Sinai Medical Centre, Beverly Hills, CA, ¹¹Centre for Rheumatology, London, United Kingdom, ¹²University College London, London, United Kingdom, ¹³State University of New York Downstate Medical Center, Brooklyn, NY, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ¹⁶Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ¹⁷University of Toronto, Toronto, ON, Canada, ¹⁸Toronto Western Hospital, Toronto, ON, Canada, ¹⁹Northwestern University, Chicago, IL, ²⁰King's College London School of Medicine, London, United Kingdom, ²¹Feinstein Institute for Medical Research, Manhasset, NY, ²²Feinstein Institute for Medical Research, New York, ²³University of Alabama at Birmingham, Birmingham, ²⁴Allegheny Health Network, Pittsburg, PA, ²⁵Lund University, Lund, Sweden, ²⁶Hairmyres Hospital, East Kilbride, United Kingdom, ²⁷Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, ²⁸Josep Font Autoimmune Diseases Laboratory, Barcelona, Spain, ²⁹Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ³⁰Emory University, Atlanta, GA, ³¹UC San Diego School of Medicine, LaJolla, CA, ³²Istanbul University, Istanbul, Turkey, ³³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ³⁴University of Manitoba, Winnipeg, Canada, ³⁵Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ³⁶Columbia University Medical Center, New York, NY, ³⁷University of Cambridge, Cambridge, United Kingdom, ³⁸University of Calgary, Calgary, AB, Canada
Background/Purpose: We reported that 7.7% (88/1137) of patients in an international inception cohort were ANA-negative at enrolment (Arthritis Care Res 2018 doi:1002/acr23712). There are no…
Abstract Number: 857 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients
Xinran Yuan ¹, Dandan Wang ¹ and Lingyun Sun², ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic), ²The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China (People's Republic)
Background/Purpose: Allogeneic mesenchymal stem cells (MSCs) exhibit immunoregulatory function in human autoimmune diseases such as systemic lupus erythematosus (SLE), but the underlying mechanisms remain incompletely…
Abstract Number: 1200 • 2019 ACR/ARP Annual Meeting
Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital
Judith Aniekwena¹, Titilope Olanipekun ² and Valery Effoe ², ¹Morehouse School of Medicine, Atlanta, GA, ²Morehouse School of Medicine, Atlanta
Background/Purpose: Influenza infection constitutes a significant cause of morbidity and mortality in patients living with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The risk…
Abstract Number: 1787 • 2019 ACR/ARP Annual Meeting
The Glucocorticoid-Induced Protein GILZ Represent a Checkpoint in the IFN Program in SLE
Eric Morand¹, Champa Nataraja ¹, Melissa Northcott ¹, Wendy Dankers ¹, Jacqueline Flynn ¹, Wendy Zhu ¹, Taylah Bennett ¹, Mehnaz Pervin ¹, Brendan Russ ¹, James Harris ¹ and Sarah Jones ¹, ¹Monash University, Melbourne, Victoria, Australia
Background/Purpose: Given the primacy of Type I interferon (IFN) pathways in SLE pathogenesis, and the near-ubiquity of glucocorticoid (GC) use in SLE treatment, clarifying the…
Abstract Number: 2540 • 2019 ACR/ARP Annual Meeting
Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt
Yasmin Hussein¹ and Yousra Sadeq ¹, ¹Mansoura University Hospital, Mansoura, Egypt
Background/Purpose: SLE is a systemic inflammatory and autoimmune disease. IL-34 plays pivotal roles in the proliferation and differentiation of mononuclear phagocyte cells, osteoclastogenesis and inflammation.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].